Literature DB >> 10887125

Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway.

K Nomura1, H Kanegane, H Karasuyama, S Tsukada, K Agematsu, G Murakami, S Sakazume, M Sako, R Tanaka, Y Kuniya, T Komeno, S Ishihara, K Hayashi, T Kishimoto, T Miyawaki.   

Abstract

Surrogate light chains (lambda 5/VpreB) are selectively expressed in early precursors of B cells. B-cell defects in X-linked agammaglobulinemia (XLA) are caused by mutations in the gene for Bruton's tyrosine kinase. To elucidate the nature of early B-lineage cells in bone marrow (BM), samples from 13 XLA patients and 24 healthy controls of different ages were comparatively analyzed using an antihuman VpreB monoclonal antibody. Expression of surrogate light (SL) and mu-heavy chains were examined after cell membrane permeabilization because they are mainly expressed in the cytoplasm of early B-lineage cells. A flow cytometric analysis of normal BM identified 5 discrete cell types of B cells: mu(-)SL(++) (pro-B [B-cell progenitor]), mu(low)SL(++) (pre-B1a), mu(low)SL(+) (pre-B1b), mu(low)SL(- )(pre-B2), and mu(high)SL(- )(B). The large cells, presumably in cycling states, were enriched in pre-B1a cells. The frequencies of B-lineage cells in BM were higher in young children, and declined with advancing age. In contrast, XLA showed a profound reduction in BM B-lineage cells. In XLA BM, an expansion of pro-B cells with some small pre-B1a cells was marked, but other cells were negligible. These observations illustrate a B-cell maturation defect in XLA as well as a normal human B-cell differentiation pathway. The results suggest that the genetic defect in XLA may impede the evolution of pro-B cells beyond the earlier pre-B stage into the later stage of pre-B cells in B-cell development. (Blood. 2000;96:610-617)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887125

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Genes required for B cell development.

Authors:  Mary Ellen Conley
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 2.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

3.  XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.

Authors:  Jeroen G Noordzij; Sandra de Bruin-Versteeg; Nico G Hartwig; Corry M R Weemaes; Egbert J A Gerritsen; Eva Bernatowska; Stefaan van Lierde; Ronald de Groot; Jacques J M van Dongen
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

4.  Mutations in Bruton's tyrosine kinase impair IgA responses.

Authors:  Noriko Mitsuiki; Xi Yang; Sophinus J W Bartol; Christina Grosserichter-Wagener; Yoshiyuki Kosaka; Hidetoshi Takada; Kohsuke Imai; Hirokazu Kanegane; Shuki Mizutani; Mirjam van der Burg; Menno C van Zelm; Osamu Ohara; Tomohiro Morio
Journal:  Int J Hematol       Date:  2015-01-15       Impact factor: 2.490

5.  Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombinase activating gene (RAG) mutations.

Authors:  K Agematsu; H Nagumo; S Hokibara; T Mori; T Wada; A Yachie; H Kanegane; T Miyawaki; K Sugita; H Karasuyama; A Komiyama
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 7.  Primary B-cell immunodeficiencies.

Authors:  Tukisa Smith; Charlotte Cunningham-Rundles
Journal:  Hum Immunol       Date:  2018-10-22       Impact factor: 2.850

8.  Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina.

Authors:  Natalia Basile; Silvia Danielian; Matias Oleastro; Sergio Rosenzweig; Emma Prieto; Jorge Rossi; Adriana Roy; Marta Zelazko
Journal:  J Clin Immunol       Date:  2008-08-02       Impact factor: 8.317

9.  Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.

Authors:  Cornelia Brunner; Hans Wolfgang Kreth; Hans D Ochs; Volker Schuster
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

Review 10.  Role of the BCR complex in B cell development, activation, and leukemic transformation.

Authors:  Susan R Rheingold; Valerie I Brown; Junjie Fang; Jenny M Kim; Stephan A Grupp
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.